Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Tesaro is celebrating the approval of its cancer-treatment drug by seeking a sale, per WSJ.
Why it matters: Tesaro makes cancer drugs, and a sale could induce a bidding war among other drug companies who want a piece of the competitive space that has also commanded extremely high prices.
The numbers: The company most recently had a market value of $7.4 billion, which means should a bidder be approved, the sale could be as high as $9 billion, WSJ notes.
The drug: It's called Zejula and it helps treat ovarian cancer. Analysts estimated that Zejula sales could hit $1.9 billion by 2022, but only if it expands to treat other types of cancer (like breast cancer).